MRVI earnings analysis
What we found in MRVI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Maravai reported Q2 2026 revenue of $51.442 million and diluted EPS of $(0.02), with revenue lower than the unusually strong $66 million Q1 but higher than approximately $47 million in the prior-year quarter. Liquidity was $70.1 million against $150.0 million of Term Loan debt, while variable-rate exposure creates sensitivity to higher interest rates. The filing states that there were no material changes to the risk factors from the 2025 10-K and does not provide new quantitative guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Improved Year Over Year
- Q2 2026 revenue was $51.442 million, down from $66 million in Q1 2026 but up from approximately $47 million in Q2 2025. Reported diluted EPS was $(0.02), unchanged sequentially and improved from $(0.27) year over year.
- Cash Balance Remains Material
- Cash and cash equivalents totaled $70.1 million as of June 30, 2026, providing liquidity against the company’s debt obligations.
- Revolver Remained Undrawn
- The company had $150.0 million of outstanding Term Loan borrowings and no borrowings under its Revolving Credit Facility at June 30, 2026.
- Controls Were Effective
- Management stated that disclosure controls were effective at a reasonable assurance level as of June 30, 2026, and that there were no material changes in internal control over financial reporting during the quarter.
- International Mix Remains Significant
- International sales represented 40.0% of revenue in Q2 2026 and 43.7% for the first six months, although substantially all such sales were denominated in U.S. dollars.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Variable-Rate Debt and Interest Expense
- Borrowings under the 2026 Credit Agreement carry variable rates based on Term SOFR plus 5.00% or an alternate base rate plus 4.00%. A hypothetical 100-basis-point rate increase would have raised interest expense by approximately $0.5 million for the quarter and $1.2 million for the six-month period.
- Debt Exceeds Cash
- The company had $150.0 million of Term Loan borrowings compared with $70.1 million of cash and cash equivalents as of June 30, 2026. This creates meaningful balance-sheet leverage and limits financial flexibility if operating cash generation weakens.
- Growing Foreign-Currency Exposure
- International sales were 40.0% of quarterly revenue and 43.7% of six-month revenue. Although sales are substantially denominated in U.S. dollars, management said expanding international operations could increase exposure to foreign-exchange fluctuations, and the company has no foreign-currency hedging arrangements.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.02
What they said about what is next.
The supplied 10-Q text does not provide quantitative revenue or EPS guidance, nor does it state whether the prior full-year revenue outlook of $205 million-$215 million was maintained, raised, lowered, or withdrawn.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 8, 2026
- Maravai LifeSciences reported strong results for Q1 2026 with a revenue of $65.8 million, exceeding expectations of $53.3 million, and showing a significant increase from $46.9 million in Q1 2025. The company achieved a…
- 10-K · February 26, 2026
- Maravai (MRVI) operates two reportable segments — TriLink (64% of 2025 revenue) and Cygnus (36% of 2025 revenue) — centered on nucleic acid products and biologics safety testing. The company shows a meaningful IP…
- 10-Q · November 7, 2025
- Maravai LifeSciences reported a significant decline in Q3 2025 revenue, which dropped to $41.63 million from $69.03 million year-over-year, reflecting a 39.6% decrease. Net loss attributed to shareholders was $25.56…
- 10-Q · May 12, 2025
- Maravai reported Q1 revenue of $46.85M and a net loss of $52.853M (net loss per Class A share $(0.21)). Revenue declined year-over-year from $64.179M to $46.85M, while loss from operations widened to $49.162M, driven in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MRVI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever